Amerant (AMTB) Q3 2026 Earnings Call Transcript

Amerant reported Q3 net income of $25.7 million, or $0.65 per diluted share, up from $21.0 million and $0.53 in Q2; net interest margin expanded 25 basis points to 3.77%, and management said return on assets reached its 1% target. Gross loans rose 3% to $7.1 billion and nonperforming loans fell 12.6% to $149.5 million, while deposits declined $109.6 million to $8.2 billion. Q4 guidance calls for NIM of 3.65%–3.70%, loans of about $7.3 billion, and deposits of about $8.5 billion; the board also authorized up to $50 million in share repurchases through Dec. 31, 2027. Tangible common equity declined amid unrealized AFS portfolio losses as market yields rose by more than 100 basis points.

Analysis

AMTB’s earnings improvement looks real but less repeatable than the headline run-rate suggests. Q3 NIM benefited from NPL-related collections and early loan exits; management’s Q4 guide itself implies a sequential step-down. The key test is whether loan repricing and deposit-cost discipline can offset that normalization—not whether Q3’s peak margin can be repeated.

Funding quality is the bigger swing factor. The $270 million shift to noninterest-bearing classification improves reported mix, but is not new funding; meanwhile, large domestic-provider exits and variable international flows leave the deposit-growth bridge dependent on execution. International balances may be low-cost, but create concentration, liquidity-management and compliance sensitivity that a benign quarter cannot resolve. Likewise, falling criticized loans partly reflect payoffs, not necessarily broad borrower cures; higher specific reserves and planned charge-offs warrant continued scrutiny.

Capital returns are not unambiguously accretive: repurchases above tangible book value, alongside 7% holding-company notes, trade current capital flexibility for per-share growth. AFS marks may recover if yields ease, but renewed rate increases would pressure tangible equity and potentially constrain buybacks. Near term, expect volatility around deposit realization and Q4 NIM; over 1–3 months, track year-end balances and charge-offs; over 6–18 months, the thesis depends on revenue growth outpacing hiring and sustaining efficiency gains. Consensus may over-credit the 1%+ ROA print as a durable baseline before funding and credit quality are proven.

Key Decisions for Investors

• Do not chase the Q3 earnings print. Keep AMTB on watch; consider a small long only if the stock weakens without deterioration in deposit trends and management reaffirms the Q4 NIM range.
• For a tactical relative-value expression, pair a modest AMTB long with a short KRE position to reduce broad regional-bank beta; size for company-specific funding and credit risk, and avoid adding ahead of year-end deposit data.
• Reassess after Q4 results: thesis confirmation requires deposit growth toward guidance, NIM within the guided range excluding unusual recoveries, and no renewed rise in classified or nonperforming loans. Deposit shortfall, materially weaker NIM, or worsening specific reserves would falsify the constructive view.